百利天恒iza-bren食管鳞癌适应症正式纳入优先审评

Core Viewpoint - The article highlights that BaiLi TianHeng's dual antibody ADC, iza-bren (BL-B01D1), has been included in priority review by the CDE for the treatment of recurrent or metastatic esophageal squamous cell carcinoma in patients who have failed previous PD-1/PD-L1 monoclonal antibody combined with platinum-based chemotherapy [1] Group 1 - Iza-bren is the second indication to be included in priority review, following its first indication for nasopharyngeal carcinoma, which was prioritized in September 2025 [1] - The new drug application for the nasopharyngeal carcinoma indication was officially accepted by the CDE in November 2025 [1]